Europe — EMA
Omjjara (Momelotinib)
Momelotinib, the active ingredient in Omjjara, is a targeted therapy presented as a tablet for oral use. It is being investigated for the treatment of myelofibrosis and related blood disorders in adult patients.
Request sourcing
What is Momelotinib?
Momelotinib, the active ingredient in Omjjara, is a targeted therapy presented as a tablet for oral use. It is being investigated for the treatment of myelofibrosis and related blood disorders in adult patients. GNH USA supplies Omjjara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Omjjara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Momelotinib used for?
Omjjara (momelotinib) is a Jan‑Jan
- Myelofibrosis: reduces ... - ... ... ....
What are the side effects of Momelotinib?
Common
What precautions apply to Momelotinib?
